Add-On CICA Antibodies
The Add-On CICA Antibodies test detects serum antibodies to cytokine-activated cellular epitopes, a proprietary marker used in functional-immunology evaluation of chronic inflammatory symptoms. It is an exploratory tool not part of standard autoimmune guidelines, ordered to investigate immune dysregulation in treatment-resistant fatigue, pain, and cognitive complaints when conventional…
1
Biomarkers
Blood (serum)
Sample
7–10 business days
Turnaround
No
Fasting
What is the CICA Antibodies test?
The Add-On CICA Antibodies test is an exploratory serological assay that detects antibodies hypothesised to form against cellular targets during cytokine-induced immune activation. It is ordered by practitioners working within integrative, functional-medicine, or immunology-focused paradigms when a patient presents with chronic inflammatory symptoms—fatigue, widespread pain, cognitive dysfunction, or recurrent infections—that remain unexplained after standard autoimmune and inflammatory screening. Because CICA antibodies are not established biomarkers in mainstream rheumatology or immunology guidelines, the test functions as a supplementary investigation rather than a first-line diagnostic. Practitioners order it to explore immune dysregulation pathways that may not be captured by conventional ANA, RF, or CCP testing, with the understanding that interpretation is exploratory and management is directed toward immune modulation and trigger mitigation rather than treatment of a named autoimmune disease.
What does the CICA Antibodies test measure?
Cytokine-induced cellular activation antibodies represent a class of autoantibodies hypothesised to arise when immune dysregulation leads to antibody formation against cellular epitopes exposed or modified during cytokine-driven inflammatory responses. The concept proposes that chronic inflammation alters cell-surface or intracellular antigens, rendering them immunogenic; circulating antibodies to these neoantigens may then perpetuate or amplify inflammatory signalling. The CICA assay was developed to detect such antibodies in serum using proprietary cell-based immunoassay platforms that expose target cells to defined cytokine conditions before measuring antibody binding.
The CICA antibodies test is positioned as an adjunct tool in the functional-immunology assessment of patients with chronic, treatment-resistant inflammatory or autoimmune symptoms when conventional serological markers are unrevealing. Proponents suggest that CICA positivity may help explain persistent fatigue, musculoskeletal pain, cognitive complaints, or multi-system symptoms attributed to immune dysregulation. The test is not a diagnostic for any recognised autoimmune disease and is not part of standard rheumatological or immunological guidelines; its clinical validity and utility remain topics of research and debate, with limited peer-reviewed validation outside the developing laboratory.
Why is the CICA Antibodies test ordered?
- Functional-medicine evaluation of chronic fatigue, brain fog, and multi-system symptoms when conventional autoimmune and inflammatory markers are negative or equivocal
- Investigation of suspected persistent immune activation or post-infectious immune dysregulation in patients with prolonged recovery from viral or bacterial illness
- Adjunct assessment in treatment-resistant fibromyalgia, myalgic encephalomyelitis/chronic fatigue syndrome, or similar functional somatic syndromes when immune contributions are considered
- Exploration of immune mechanisms in patients with recurrent inflammatory flares, unexplained arthralgias, or myalgias without definitive rheumatological diagnosis
- Integrative evaluation of food sensitivity, environmental reactivity, or mould-illness frameworks where immune dysregulation is hypothesised
- Monitoring response to immune-modulating interventions—dietary modification, supplement protocols, or biologics—in functional-immunology practice
- Research or case-series investigation of novel immune markers in chronic inflammatory conditions with limited diagnostic biomarkers
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
No
Collection method
Venipuncture at patient service centre
Turnaround
7–10 business days
Collection notes
Phlebotomy required; serum separator tube. Follow Cell Science Systems' specimen collection and shipping instructions precisely, as the assay is cell-based and requires stable antibody and intact reagent conditions. Avoid grossly haemolysed samples. Note timing relative to acute infections, vaccinations, or initiation of immune-modulating therapy.
Specimen requirements
Minimum 1–2 mL serum (check laboratory protocol). Serum must be separated promptly and shipped refrigerated or frozen per Cell Science Systems' instructions; temperature excursions or delays may compromise assay validity.
What can affect CICA Antibodies results?
Active immune stimulation from infection or recent immunisation may transiently alter cytokine profiles and cellular activation states, potentially influencing antibody detection in a cell-based assay; timing relative to acute events should be noted.
Corticosteroids, biologics targeting cytokines (TNF inhibitors, IL-6 inhibitors), or conventional DMARDs can suppress antibody production and cytokine-induced cellular responses, reducing assay signal; consider baseline testing before therapy initiation if monitoring is planned.
Cell-based assays require viable reagent cells and intact antibody; delays in shipment, temperature excursions, or haemolysis may affect assay performance; adherence to the laboratory's collection and transport protocol is essential.
Established autoimmune conditions (rheumatoid arthritis, systemic lupus) and their treatments create complex immune and cytokine milieus that may increase non-specific antibody binding; results must be interpreted in context of known diagnoses and concurrent therapies.
Cytokine levels and immune cell activation exhibit circadian rhythms and respond to acute stressors; while the assay measures antibody rather than cytokine directly, the biological context of sampling may introduce variability.
What do CICA Antibodies results mean?
Elevated
A positive CICA antibodies result is interpreted as evidence of circulating antibodies to cytokine-activated cellular epitopes, suggesting a state of immune dysregulation or persistent inflammatory signalling. Within the functional-immunology model, positivity may help explain chronic symptoms and guide interventions aimed at reducing inflammatory triggers (diet, gut health, environmental exposures) and supporting immune balance (anti-inflammatory nutrients, stress management, targeted supplementation). It is not diagnostic of a specific autoimmune disease and should not be used to initiate disease-modifying therapy outside established clinical guidelines.
Normal
A negative CICA antibodies result indicates that cytokine-induced cellular activation antibodies were not detected at the assay threshold. This does not exclude immune dysregulation—other immune pathways, non-antibody-mediated inflammation, or subclinical activation below the detection limit may still be present. Interpretation should integrate clinical presentation, conventional inflammatory markers (CRP, ESR), and other functional-immunology assessments rather than relying on a single test.
Reduced
Not applicable. The assay reports positive or negative (or semiquantitative titer if provided); a negative result is the reference state.
Note: The CICA antibodies assay is a proprietary, method-specific test developed by Cell Science Systems, and its clinical validity and utility have not been established in peer-reviewed, multi-centre studies or incorporated into mainstream immunology or rheumatology guidelines. Results should be considered exploratory and interpreted by practitioners familiar with functional-immunology frameworks. A positive result does not diagnose a recognised autoimmune disease, and management should focus on modifiable triggers and immune support rather than aggressive immunosuppression. Clinicians unfamiliar with the assay should not use it to alter standard-of-care diagnostic or therapeutic pathways.
Frequently asked questions
CICA antibodies are cytokine-induced cellular activation antibodies—serum autoantibodies hypothesised to form against cellular targets exposed or modified during cytokine-driven inflammation. The assay is a proprietary functional-immunology tool developed by Cell Science Systems.
How to access the CICA Antibodies test
The CICA Antibodies reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Vojdani A, et al. Detection of antibodies against human and plant aquaporins in patients with multiple sclerosis. Autoimmune Dis. (2011)
- Vojdani A. A potential link between environmental triggers and autoimmunity. Autoimmune Dis. (2014)
- Kharrazian D. Exposure to environmental toxins and autoimmune conditions. Integr Med (Encinitas). (2021)
- Institute for Functional Medicine. Clinical approaches to immune dysregulation and chronic inflammation. (2022)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.